What is TG Therapeutics's revenue?

TG Therapeutics (TGTX) generated $700.3M in revenue over the trailing twelve months, up 81.3% year over year.

Is TG Therapeutics profitable?

TG Therapeutics reported $461.9M in net income over the trailing twelve months, a 66.0% net margin.

What are TG Therapeutics's profit margins?

Gross margin is 83.1% and operating margin is 21.3%, with a 66.0% net margin.

What is TG Therapeutics's earnings per share?

TG Therapeutics's diluted EPS over the trailing twelve months is $2.87.

Where does TG Therapeutics's income statement data come from?

Every line is extracted from TG Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

TG Therapeutics TGTX Income Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY QoQ

Simplified Detailed

	TTM Q1 '26	TTM Q4 '25	TTM Q3 '25	TTM Q2 '25	TTM Q1 '25
Total revenue	$700.35M+13.6%	$616.29M+15.9%	$531.9M+17.1%	$454.07M+17.5%	$386.39M+17.4%
Total cost of revenue	$118.68M+17.8%	$100.71M+29.2%	$77.97M+31.7%	$59.22M+21.9%	$48.59M+26.2%
Gross profit	$581.67M+12.8%	$515.57M+13.6%	$453.93M+15.0%	$394.85M+16.9%	$337.8M+16.3%
Gross margin	83.1%-0.6pp	83.7%-1.7pp	85.3%-1.6pp	87%-0.5pp	87.4%-0.9pp
Research and development	$162.25M+1.3%	$160.22M+12.1%	$142.9M+17.0%	$122.16M+13.2%	$107.93M+14.5%
Selling, general and administrative	$269.92M+16.3%	$232.03M+11.4%	$208.25M+11.5%	$186.85M+9.9%	$170.05M+10.2%
Total costs & expenses	$550.85M+11.7%	$492.96M+14.9%	$429.12M+16.5%	$368.22M+12.8%	$326.57M+13.8%
Operating income	$149.5M+21.2%	$123.32M+20.0%	$102.78M+19.7%	$85.85M+43.5%	$59.82M+42.7%
Operating margin	21.3%+1.3pp	20%+0.7pp	19.3%+0.4pp	18.9%+3.4pp	15.5%+2.7pp
Interest expense	$27.64M+3.4%	$26.73M-1.9%	$27.26M-13.1%	$31.37M+9.6%	$28.63M+18.5%
Other income (expense), net	-$27.21M-70.8%	-$15.93M-6.0%	-$15.03M+23.9%	-$19.74M-9.2%	-$18.08M-10.7%
Income before income taxes	$122.29M+13.9%	$107.39M+22.4%	$87.75M+32.7%	$66.11M+58.4%	$41.74M+63.1%
Income tax expense	-$361.67M0.0%	-$361.85M-0.6%	-$359.72M-6,466%	$5.65M+118%	$2.59M+17.1%
Net income	$461.9M+3.3%	$447.18M-0.1%	$447.47M+640%	$60.46M+54.4%	$39.15M+67.4%
Net margin	66%-6.6pp	72.6%-11.6pp	84.1%+70.8pp	13.3%+3.2pp	10.1%+3.0pp
Diluted earnings per share	$2.87+3.2%	$2.780.0%	$2.78+651%	$0.37+54.2%	$0.24+71.4%
EBITDA	$149.58M+21.2%	$123.38M+20.0%	$102.83M+19.7%	$85.89M+43.5%	$59.87M+42.6%
EBITDA margin	21.4%+1.3pp	20%+0.7pp	19.3%+0.4pp	18.9%+3.4pp	15.5%+2.7pp
EBIT	$149.5M+21.2%	$123.32M+20.0%	$102.78M+19.7%	$85.85M+43.5%	$59.82M+42.7%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Ask your AI about TG Therapeutics.

Connect your AI assistant and get a quick read on the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is TG Therapeutics's revenue?: TG Therapeutics (TGTX) generated $700.3M in revenue over the trailing twelve months, up 81.3% year over year.
Is TG Therapeutics profitable?: TG Therapeutics reported $461.9M in net income over the trailing twelve months, a 66.0% net margin.
What are TG Therapeutics's profit margins?: Gross margin is 83.1% and operating margin is 21.3%, with a 66.0% net margin.
What is TG Therapeutics's earnings per share?: TG Therapeutics's diluted EPS over the trailing twelve months is $2.87.
Where does TG Therapeutics's income statement data come from?: Every line is extracted from TG Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.